INTRODUCTION {#S1}
============

CD4^+^ Foxp3^+^ regulatory T cells (Treg) play a pivotal role in immune tolerance and tissue homeostasis ([@R29]; [@R54]). The deficit of Treg number or function causes lymphoproliferative and multi-organ autoimmune disorders ([@R1]; [@R55]; [@R63]). Conversely, excessive Treg accumulation promotes persistent infection and cancer ([@R13]; [@R17]; [@R41]; [@R42]; [@R73]). Therefore, homeostatic regulation of the differentiation and function of Tregs are essential for these cells to exert their physiological roles ([@R6]; [@R37]; [@R57]). Several mechanisms have been proposed to maintain Treg homeostasis, including the balance between proliferation and apoptosis ([@R48]), the dependence and negative feedback of Treg on paracrine interleukin-2 (IL-2) ([@R37]), and metabolic regulations ([@R24]; [@R77]).

TCF1 (encoded by *Tcf7*) plays a critical role in thymic T cell development and lineage commitment ([@R23]; [@R26]; [@R58]; [@R68]; [@R78]). In the periphery, TCF1 is required for self-renewal of memory CD8^+^ T cells and the repression of effector CD8^+^T cells ([@R21]; [@R27]; [@R65]; [@R80]; [@R81]). In peripheral CD4^+^ T cell lineage, TCF1 and LEF1 have been shown to promote the development and function of T follicular helper (Tfh) cells ([@R8]; [@R72]; [@R74]). As for Tregs, our earlier studies have found that TCF1 and LEF1 were among a list of transcription factors (TFs) that could cooperate with Foxp3 to "lock in" a Treg transcriptional program ([@R20]). However, which modules of Treg activities are specifically controlled by TCF1 or LEF1 remains unclear. Previous studies have shown that the activation of β-catenin negatively impacted thymic Treg development ([@R2]), or Treg suppressive function ([@R67]). In those studies, TCF1 was implicated to act as a downstream regulator to dampen Treg thymic generation or Foxp3 transcriptional activity. However, Ding et al. reported that β-catenin activation did not alter Treg function but instead improved their survival, so that fewer β-catenin^+^ Tregs were required to suppress CD45RB^hi^ cell-induced colitis ([@R14]). Paradoxically, another study reported that sustained activation of β-catenin in Tregs contributed to the development of colitis and cancer ([@R31]). Thus, how exactly TCF1 and LEF1 impact Treg function remains to be defined.

In this study, we directly assessed the role of TCF1 and LEF1 in Treg physiology. Based on the expression of TCF1 and LEF1, we proposed a revised model of peripheral Treg differentiation, in which a subset of TCF1^+^ CD44^hi^ "aTregs" was identified. Importantly, Treg-specific deletion of TCF1 and LEF1 led to systemic autoimmunity. To determine the underlying mechanisms, we used both gain- and loss-of-function approaches to modulate TCF1 and LEF1 and examined the differentiation, survival, functional specification, and suppressive capacity of Tregs. Our data revealed critical roles of TCF1 and LEF1 in regulating the competitive survival of pSTAT5^+^ aTreg subset and the development of Tfr to prevent autoimmune diseases.

RESULTS {#S2}
=======

Gradient Expression of TCF1 and LEF1 Distinguishes Peripheral Tregs into Distinct Subsets {#S3}
-----------------------------------------------------------------------------------------

We examined the expression of TCF1 and LEF1 on protein level in Tregs. We found that all CD62L^+^ CD44^lo^ cells were TCF1^+^ ([Figure 1A](#F1){ref-type="fig"}, middle panel, R1 gating). In contrast, CD62L^−^ CD44^hi^ Tregs can be divided into two distinct subsets: TCF1^+^ (R2) and TCF1^−^ (R3) ([Figures 1A](#F1){ref-type="fig"}, [S1A](#SD1){ref-type="supplementary-material"}, and [S1B](#SD1){ref-type="supplementary-material"}). The complete "tuning off" of TCF1 expression in the R3 subset was confirmed by analyzing the expression of TCF1 in *Tcf7^gfp/gfp^* mice (*Tcf7* encodes TCF1) and *Foxp3^Cre^Tcf7^fl/fl^* mice ([Figure S1C](#SD1){ref-type="supplementary-material"}). Back-gating of the three subsets onto the CD44/CD62L plot showed that the expression of CD44 in R3 was slightly but significantly higher than that in R2 ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). The compositions of these three Treg subsets were similar across different peripheral lymphoid organs at steady state (B6 mice, 7--9 weeks of age), with R1 the most, and R3 the least, abundant ([Figure 1C](#F1){ref-type="fig"}). However, the proportions of R3 dramatically increased in non-lymphoid tissues, such as pancreas and intestinal lamina propria ([Figure S1D](#SD1){ref-type="supplementary-material"}). Aging is another factor impacting the compositions of Treg pool, characterized by significantly increased percentage of TCF1^−^ R3 subset ([Figures 1D](#F1){ref-type="fig"} and [S1E](#SD1){ref-type="supplementary-material"}). Different from the clear ON/OFF switch of TCF1 among these newly defined Treg subsets, the expression of LEF1 exhibited a gradient reduction and was negative (based on isotype control) in the R3 subset ([Figures 1E](#F1){ref-type="fig"}, [S1F](#SD1){ref-type="supplementary-material"}, and [S1G](#SD1){ref-type="supplementary-material"}). Interestingly, immunostaining of spleen sections showed that TCF1^+^ Tregs were enriched in the T cell zone, whereas TCF1^−^ Tregs formed clusters in the red pulp or marginal zone ([Figure S1H](#SD1){ref-type="supplementary-material"}). Thus, gradient expression of TCF1 (and LEF1 to a less extent) distinguishes peripheral Tregs into three subpopulations.

TCF1^+^ and TCF1^−^ Tregs Have Distinct Transcriptomes {#S4}
------------------------------------------------------

To further characterize the differences among these Treg subsets, we sorted each of them from pooled spleens and lymph nodes (LNs) of *Tcf7*^gfp^ reporter mice ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}) and performed RNA sequencing (RNA-seq) of their transcriptomes. For data analysis, we first used the principal-component analysis (PCA) to parse out the similarities and differences among their transcriptomes. PCA showed that the replicates within the same subset were grouped together, whereas the distinctions between different subsets were clearly revealed. Interestingly, even though both the R2 and R3 subsets were CD62L^lo^ CD44^hi^, the divergence of their transcriptomes between R2 and R3 was bigger than that between R2 and R1, based on the principal component 1 (which explained 94% of the variances) ([Figure 2A](#F2){ref-type="fig"}).

To more accurately assess the activation status in each of the three subsets, we superimposed T cell activation gene signature ([@R25]) onto our RNA-seq datasets. Using the volcano plots, we can determine to what extent a T cell activation signature was over- or under-represented. Compared to the R1 subset, both the R2 and R3 subsets exhibited a clear profile of T cell activation, depicted by the numbers of upregulated T cell activation signature genes ([Figure 2B](#F2){ref-type="fig"}). The comparison between the R2 and R3 subsets revealed that the latter (TCF1^−^) gained a further elevated degree of activation.

To parse out the links between differentially expressed (DE) genes and Treg phenotype and function, we examined the expression patterns of two panels of genes across the three Treg subsets. The first panel (listed in [Figure 2C](#F2){ref-type="fig"}) was composed of TFs that have been reported to participate in certain aspects of Treg differentiation and/or function. Using row-normalization algorithm, these 22 TFs fell into three clusters. In cluster 1 (including *Tcf7*, *Gata1*, *Bach2*, *Ikzf1*, *Lef1*, *Myb*, and *Satb1*), all TFs exhibited a stepwise downregulation and were noticeably under-represented in the R3 (TCF1^−^) subset. In contrast, the TFs in cluster 3 (including *Irf4*, *Ikzf2*, *Gata3*, *Prdm1*, and *Tbx21*) were significantly over-represented in the R3 subset. The rest of TFs in the list (cluster 2, including *Jun, Fos*, and *Ikzf4*) in this analysis did not show a clear pattern. However, interestingly, the expression of *Bcl6* (a TF associated with Tfh and Tfr development) ([@R8]; [@R9]; [@R35]; [@R72]; [@R74]) was relatively higher in R2 (TCF1 ^+^ CD44^hi^) subset, compared to R1 or R3. The expression of *Ikzf2* showed a gradient increase from R1 to R3 subset ([Figure S2C](#SD1){ref-type="supplementary-material"}). We then analyzed the expression of Helios (encoded by *Ikzf2*) on protein level. Interestingly, we found that Helios^+^ Tregs comprised TCF1 ^+^ and TCF1^−^ subsets, whereas the majority of Helios^−^ Tregs were TCF1^+^ ([Figure S2D](#SD1){ref-type="supplementary-material"}). Further analysis of Helios expression in pre-gated R1, R2, and R3 showed that Helios^−^ Tregs were predominantly enriched in the R1 pool ([Figure S2E](#SD1){ref-type="supplementary-material"}).

Thus, the over- or under-representation of these TFs occurs in a Treg subset-specific manner and the ON/OFF switch of TCF1 and LEF1, not that of CD44/CD62L, explains a greater degree of the distinctions among these Treg subsets. This notion was further supported by the expression of a list of genes encoding Treg-associated surface markers and secreted effector proteins (listed in [Figure 2D](#F2){ref-type="fig"}). These genes fell into two clearly distinct clusters. Those Treg function-associated molecules (such as *Icos, Ctla4, Lag3, Il10,* and *Tigit*) were significantly upregulated in the R3 subset, whereas the genes in cluster 2 (including *S1pr1, Ly6c, Sell,* and *Ccr7*) exhibited an opposite trend of regulation.

We next evaluated the expression of Treg effector proteins and two key TFs on protein level using flow cytometry. About 80% of the R3 subset were ICOS^+^ or CD103^+^, whereas the expression levels of ICOS and CD103 were significantly lower in the R2 subset. Likewise, the expression of KLRG1, another surface marker associated with Treg terminal differentiation ([@R19]), was only detected in a fraction of R3 ([Figure 2E](#F2){ref-type="fig"}). Likewise, the expression of IRF4 and Blimp1 showed a stepwise increase across the three subsets ([Figure 2F](#F2){ref-type="fig"}), indicative of an increased need of these two TFs in Treg differentiation as previously reported ([@R11]; [@R33]). Thus, based on the RNA-seq and flow cytometric analyses, we proposed a revised model of the compositions of Treg pool in peripheral lymphoid organs. In this model, three Treg subpopulations were identified and termed resting (rTreg), activated (aTreg), and effector (eTreg), reflecting their status of activation and differentiation ([Figure 2G](#F2){ref-type="fig"}).

Treg-Specific Ablation of TCF1 and LEF1 Provokes the Spontaneous Onset of Systemic Autoimmunity {#S5}
-----------------------------------------------------------------------------------------------

To determine whether TCF1 and LEF1 affect Treg's function in immune tolerance, we took a loss-of-function approach to conditionally deplete *Tcf7* and *Lef1* in Tregs. In this regard, we crossed the mice bearing loxP-flanked *Tcf7* or *Lef1* alleles ([@R8]; [@R58]; [@R78]) with *Foxp3^YFP-Cre^* mice ([@R52]) (all on the B6 background) to generate Treg-specific ablation of *Tcf7*, or *Lef1*, or both (termed *Tcf7KO, Lef1KO,* or *dKO*, respectively). Of note, *dKO* mice began to develop immuno-pathologies from young ages (as early as 6--7 weeks old). There were several abnormalities. First, the sizes and cellularities of peripheral LNs (pLNs), not spleen, were significantly increased in *dKO* mice, compared to littermate controls ([Figure 3A](#F3){ref-type="fig"}). Second, histological analysis showed that multiple organs (including thyroid and salivary glands, lung, and small and large intestines) succumbed to immune infiltrations ([Figure 3B](#F3){ref-type="fig"}). These tissue pathologies were unlikely caused by the defects of Treg accumulation at tissue sites because the percentages and numbers of Tregs and the mean fluorescence intensities (MFIs) of Foxp3 protein were comparable, or even slightly increased, in colon lamina propria of *dKO* mice, compared to wild-type (WT) littermate controls ([Figure S3A](#SD1){ref-type="supplementary-material"}). Third, we detected an increased production of interferon (IFN)-γ, but not IL-17A, in CD4^+^ conventional T (Tconv) cells in pLNs ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}) and spleen ([Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}) of *dKO* mice. Meanwhile, the humoral immune responses were also significantly elevated in *dKO* mice, reflected by increased productions of immunoglobulin E (IgE) and IgG in the sera of these mice ([Figure 3E](#F3){ref-type="fig"}). Among the IgG subclasses, the IgG2b production was particularly increased ([Figure S3D](#SD1){ref-type="supplementary-material"}). Importantly, we found that the sera of *dKO* mice contained higher concentrations of autoantibodies, reacting to self-antigens from multi-organs including kidney, pancreas, liver, stomach, and salivary and thyroid glands ([Figure 3F](#F3){ref-type="fig"}), indicative of the manifestation of bona fide autoimmune diseases in *dKO* mice.

Thus, Treg-specific ablation of *Tcf7* and *Lef1* renders the mice susceptible for early onset of systemic autoimmunity, caused by unrestrained cellular and humoral immune responses.

The Deficiency of Tcf7 and Lef1 Does Not Impair Treg's Suppressive Capacity {#S6}
---------------------------------------------------------------------------

Given the aberrant autoimmune phenotype in *dKO* mice, we asked whether Treg's suppressive capacity was affected by conditional knockouts of *Tcf7* and *Lef1*. We used an established approach of *in vitro* coculture of dendritic cells (DCs), responder T (Tresp), and Tregs ([@R45]; [@R69]). As illustrated in [Figure 4A](#F4){ref-type="fig"}, DCs and Tresp cells were sorted and co-cultured with Tregs isolated from either WT or *dKO* mice ([Figure S4](#SD1){ref-type="supplementary-material"}), in the presence of anti-CD3 mAb. On day 4, co-cultured cells were collected and analyzed for Tresp proliferation and DC maturation. Both WT and *dKO* Tregs suppressed Tresp proliferation. Of note, *dKO* Tregs were slightly more suppressive than WT Tregs when the ratios between Treg and Tresp were relatively higher (1:2 and 1:1) ([Figure 4B](#F4){ref-type="fig"}).

Previous studies have reported that the downregulation of CD80 and CD86 on DCs is one key mechanism by which Tregs suppress effector T cells ([@R45]; [@R69]). We examined the expression of CD80 and CD86 on DCs after the coculture. In line with their suppressive capacity on Tresp cells, both WT and *dKO* Tregs downregulated the expression of CD80 and CD86 on DCs. Again, *dKO* Tregs were slightly more efficient to downregulate CD80 and CD86 ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

CTLA4 is a critical functional molecule for Treg's suppressive function via inhibiting DC maturation ([@R69]). We found that the expression of CTLA4 was comparable between *dKO* and WT Tregs ([Figure 4E](#F4){ref-type="fig"}).

Together, these results suggest that the ablation of *Tcf7* and Lef1 does not directly impair Treg's suppressive capacity.

TCF1 and LEF1 Preferentially Maintain the aTreg Pool {#S7}
----------------------------------------------------

We next asked whether TCF1 and LEF1 regulated Treg differentiation. We found that thymic Treg development was not affected by *Foxp3^Cre^*-mediated depletion of *Tcf7, Lef1,* or both ([Figure S5A](#SD1){ref-type="supplementary-material"}). In the periphery, the deficiency of *Tcf7* and *Lef1* did not alter the total numbers of bulk Tregs in secondary lymphoid organs, although the percentages of Tregs in mesenteric LNs (mLNs) and Peyer's patch (PP) of *dKO* mice were slightly reduced ([Figure S5B](#SD1){ref-type="supplementary-material"}). The expression level of Foxp3 protein was not affected (or even slightly increased in spleen and mLNs) in *dKO* mice ([Figure S5C](#SD1){ref-type="supplementary-material"}).

Because the overt systemic inflammation in *dKO* mice may influence Treg phenotype and function, we attempted to examine the impacts of TCF1 and LEF1 on Tregs under non-inflammatory conditions. To do this, we used heterozygous female *Foxp3^YFP-Cre/wt^* mice. We sorted YFP^+^ *dKO* and WT Tregs and did RNA-seq analysis. Overall, the transcriptional profiles of *dKO* and WT Tregs were tightly linear correlated ([Figure 5A](#F5){ref-type="fig"}). To parse out specific pathways that were influenced by TCF1 and LEF1, we did gene set enrichment analysis (GSEA) with a focus on the "hallmark gene sets" from the MSigDB ([@R34]; [@R60]). Interestingly, the top enriched pathways in *dKO* compared to WT Tregs were all linked to active cell cycle (E2F targets, G2M checkpoint, and Myc targets) ([Figure 5B](#F5){ref-type="fig"}). Indeed, *dKO* Tregs exhibited an over-representation of T cell activation gene signature ([Figure 5C](#F5){ref-type="fig"}) and increased rate of proliferation ([Figure 5D](#F5){ref-type="fig"}), compared to WT Tregs. At the same time, *dKO* Tregs also showed increased expression of pro-apoptotic protein Bim but not the anti-apoptotic Bcl2 ([Figure S5D](#SD1){ref-type="supplementary-material"}). On the other hand, as expected, Wnt-β-catenin signaling was more skewed toward WT Tregs. Interestingly, IL-2/STAT5 signaling was also significantly under-represented in *dKO* Tregs ([Figure 5B](#F5){ref-type="fig"}).

We next asked to what extent Treg gene signature was affected by the *Tcf7/Lef1* depletion. In this regard, we superimposed Treg signature genes ([@R20]) onto the expression-expression plot shown in [Figure 5A](#F5){ref-type="fig"}. Two-thirds of Treg signature genes were under-represented, while the remaining one-third was over-represented, in *dKO* Tregs, suggesting that different components of Treg transcriptional program were differentially influenced by TCF1 and LEF1. Based on their differential expression in our defined three subsets, the bulk Treg gene signature shown in [Figure 5A](#F5){ref-type="fig"} can be further divided into three sub-clusters, reflecting their preferential expression in r-, a-, or e-Tregs ([Figure 5E](#F5){ref-type="fig"}, left panel). We then examined how the expression of the genes in each sub-cluster was altered by *Tcf7/Lef1* depletion ([Figure 5E](#F5){ref-type="fig"}, right). Strikingly, almost all "aTreg-favorable" genes were under-represented in *dKO* samples, compared to WT controls, suggesting that TCF1 and LEF1 may have a preferential effect on aTreg differentiation.

To assess this possibility, we examined the relative abundance of each Treg subset in *dKO* mice. Because we could not use the TCF1/CD62L plot to distinguish these Treg subsets due to the lack of TCF1 expression in *dKO* Tregs, we found that ICOS can be used as a surrogate, in combination with CD62L, to gate on each subset (with \>80% overlap with the TCF1/CD62L plot) (illustrated in [Figure S5E](#SD1){ref-type="supplementary-material"}). Indeed, we found that the fraction of aTreg was significantly decreased (\~2-fold), with a simultaneously increased eTreg proportion, in *dKO* mice ([Figure 5F](#F5){ref-type="fig"}). However, unexpectedly, the percentage of rTregs was also increased. Because the majority of Helios^−^ Tregs (likely converted from Tconv cells in the periphery \[[@R64]\]) are in the rTreg pool ([Figure S2E](#SD1){ref-type="supplementary-material"}), in repeated experiments, we first separated Tregs into Helios^+^ and Helios^−^. When we gated on Helios^+^ fractions ([Figure 5G](#F5){ref-type="fig"}), again the deficiency of *Tcf7* and *Lef1* resulted in a severely diminished aTreg pool. Now the size of Helios^+^ rTreg pool was also reduced, though to a less extent. Again, we found increased percentages and numbers of eTregs in *dKO* mice ([Figure 5G](#F5){ref-type="fig"}). In contrast, the numbers and compositions of Helios^−^ Tregs were not affected by *Tcf7* and *Lef1* depletion ([Figure S5F](#SD1){ref-type="supplementary-material"}). To further determine the effect of TCF1 and LEF1 on the compositions of Treg pool, we took a gain-of-function approach by retrovirally transducing *Tcf7* (encoding TCF1) into Tregs and found that compared to control transduction, ectopic expression of *Tcf7* significantly increased aTreg proportion ([Figure 5H](#F5){ref-type="fig"}).

In summary, TCF1 and LEF1 have a modest effect on bulk Treg homeostasis but are essential for maintaining a normal aTreg pool.

TCF1 and LEF1 Promote Treg's Competitive Fitness by Regulating STAT5 Expression {#S8}
-------------------------------------------------------------------------------

We found that the percentage of CD25^+^ was significantly higher in TCF1^+^ than TCF1^−^ Tregs ([Figure 6A](#F6){ref-type="fig"}). In line with this, TCF1^+^ Tregs exhibited more potent responses to IL-2 in an *in vitro* STAT5 phosphorylation assay ([Figure 6B](#F6){ref-type="fig"}). In addition, the expression of both *Stat5a* and *Stat5b* was also relatively higher in TCF1^+^ Tregs, compared to TCF1^−^ counterparts ([Figure S6A](#SD1){ref-type="supplementary-material"}). Together, these findings suggest a positive correlation between TCF1 and STAT5 in Tregs.

Next, we asked whether the modulation of TCF1 and LEF1 in Tregs would affect their responsiveness to IL-2 and STAT5 activation. GSEA analysis showed that IL-2/STAT5 signaling was significantly under-represented in *dKO* Tregs ([Figure 6C](#F6){ref-type="fig"}). Consistent with this, IL-2-stimulated STAT5 phosphorylation was less efficient in *dKO* Tregs ([Figure 6D](#F6){ref-type="fig"}, left). Importantly, the intensity of pSTAT5 in *dKO*, not WT Tregs, fell to the same level as that in activated CD4^+^ non-Tregs ([Figures 6D](#F6){ref-type="fig"}, right, and [S6B](#SD1){ref-type="supplementary-material"}), suggesting that compared to WT Tregs, *dKO* Tregs lost the competitive advantage for IL-2. To understand what caused the defective IL-2/STAT5 signaling in *dKO* Tregs, we first examined CD25 expression and found no difference between *dKO* and WT Tregs ([Figure S6C](#SD1){ref-type="supplementary-material"}). Next, in an *ex vivo* assay, we found that about 30% of WT Tregs were readily positive for total STAT5 protein ([Figure 6E](#F6){ref-type="fig"}), and the same STAT5^hi^ population was also positive for pSTAT5. *Ex vivo* TCF1^+^ Tregs exhibited a higher degree of STAT5 expression and activation than that in TCF1^−^ Tregs ([Figure S6D](#SD1){ref-type="supplementary-material"}). In *dKO* Tregs, both total STAT5 and pSTAT5 were significantly reduced ([Figure 6E](#F6){ref-type="fig"}). Thus, the impaired responsiveness to IL-2 in *dKO* Tregs was more likely due to the reduced expression of total STAT5 protein and reduced pSTAT5 as a consequence. Using chromatin immunoprecipitation (ChIP)-PCR, we found that TCF1 can also bind to *Stat5b* promoter in Tregs ([Figure 6F](#F6){ref-type="fig"}). Thus, in Tregs, TCF1 acts upstream of STAT5 to regulate its expression.

We next assessed whether this compromised responses to IL-2 in *dKO* Tregs would affect their survival *in vivo*. In this regard, we isolated splenic CD4^+^ T cells from WT or *dKO* mice, transferred them into *Tcrα* ^−/−^ mice, and analyzed the reconstitution of donor cells 5 weeks later. Treg compartment was reconstituted in secondary lymphoid organs in recipient mice that have been transferred with WT CD4^+^ T cells. However, Treg reconstitution was significantly diminished in recipient mice received CD4^+^ T cells derived from the *dKO* donors ([Figure 6G](#F6){ref-type="fig"}), indicative of an impaired survival of *dKO* Tregs *in vivo* under lymphopenic conditions. To more directly assess the competitive fitness between WT and *dKO* Tregs, we did co-transfer experiments by mixing splenic CD4^+^ T cells from WT (CD45.1^+^) and *dKO* (CD45.2^+^) mice at a ratio of 3:1 before transferring them into *Tcrα* ^−/−^ mice. In parallel, as controls, a mixture of CD45.1 and CD45.2 splenic CD4^+^ T cells (both were WT cells from *Foxp3^Cre^* mice) at a ratio of 3:1 was transferred into the *Tcrα* ^−/−^ mice. After 5 weeks, we found that WT Tregs were comparably reconstituted from both CD45.1 and CD45.2 donors. By contrast, the reconstitution of *dKO* Tregs was significantly diminished ([Figure 6H](#F6){ref-type="fig"}). Consistently, the degree of STAT5 activation in residual *dKO* Treg was significantly lower, compared to that in co-transferred WT Tregs ([Figure 6H](#F6){ref-type="fig"}). Together, these data showed that *Tcf7/Lef1*-deficient Tregs failed to compete with WT Tregs, or activated Tconv cells, for survival.

The MFIs of Foxp3 on a per cell basis were comparable in re-constituted Tregs from either *dKO* or WT mice ([Figure S6E](#SD1){ref-type="supplementary-material"}). The production of inflammatory cytokines (such as IFN-γ and IL-17A) was slightly (not significantly) increased in Tregs deficient for *Tcf7, Lef1,* or both ([Figure S6F](#SD1){ref-type="supplementary-material"}). It has been reported that Tregs lose Foxp3 expression when transferred into lymphopenic recipients ([@R16]; [@R22]). We asked whether *dKO* Tregs exhibited a higher degree of instability under such conditions. In this regard, we transferred highly purified congenically labeled WT and *dKO* Tregs into *Tcrα*^−/−^ mice and found that the percentages of Foxp3^−^ "ex-Treg" cells were comparable between WT and *dKO* donors, suggesting that the depletion of *Tcf7/Lef1* did not exacerbate Treg's instability under lymphopenic conditions ([Figure S6G](#SD1){ref-type="supplementary-material"}).

Next, we assessed whether the defect of *dKO* Treg survival can be corrected by ectopic expression of *Tcf7* or constitutively activated *STAT5 (caSTAT5)*. In this regard, we isolated CD4^+^ T cells from pooled spleen and pLNs of *dKO* mice, transduced these cells with *Tcf7, caSTAT5* ([@R28]; [@R44]), or control retroviruses and transferred them into *Tcrα*^−/−^ mice and analyzed them 3 or 5 weeks later. We found that ectopic expression of *caSTAT5* was able to rescue the survival of *dKO* Tregs in lymphopenic hosts ([Figure S6H](#SD1){ref-type="supplementary-material"}). Similarly, transduction of *dKO* Tregs with *Tcf7*-expressing retroviruses also significantly improved the *in vivo* survival of these cells ([Figure S6H](#SD1){ref-type="supplementary-material"}). Next, we did competition assays by mixing congenically labeled splenic CD4^+^ T cells from *dKO* and WT mice at a 1:1 ratio and transduced them with either *caSTAT5, Tcf7*, or control retroviruses and then transferred them into *Tcrα* ^−/−^ mice. After 3 weeks, we found that again the transduction of *caSTAT5* into *dKO* Tregs significantly improved the reconstitution of these cells. Importantly, *caSTAT5* had a more profound effect on *dKO* Tregs (31-fold increase), compared to WT Tregs (1.9-fold increase) ([Figure 6I](#F6){ref-type="fig"}), further supporting the notion that STAT5 acts downstream of TCF1 to promote Treg's competitive survival. Interestingly, under these competition conditions, transduction of *Tcf7* into *dKO* Tregs was less efficient in rescuing their survival, compared to that in WT Tregs ([Figures 6I](#F6){ref-type="fig"} and [S6I](#SD1){ref-type="supplementary-material"}, filled versus open yellow dots) or non-competitive settings ([Figure S6H](#SD1){ref-type="supplementary-material"}). This was due to the different amounts of TCF1 protein after retroviral transduction, because, while the expression of TCF1 in *dKO* Tregs was markedly increased after *Tcf7-RV* transduction, it did not reach the level of that in *Tcf7-RV*-transduced WT Tregs ([Figure 6I](#F6){ref-type="fig"}, bottom left). More interestingly, we found that *caSTAT5* transduction significantly enhanced the expression of LEF1 (not TCF1) ([Figure 6I](#F6){ref-type="fig"}), indicative of a feedforward loop of TCF1-STAT5-LEF1 in promoting Treg competitive fitness. Last, using the gating strategy illustrated in [Figure S5E](#SD1){ref-type="supplementary-material"}, we found that aTreg subset was preferentially reconstituted by retroviral transduction of either *Tcf7* or *caSTAT5* ([Figure S6J](#SD1){ref-type="supplementary-material"}).

In summary, TCF1 regulates the expression of STAT5 in Tregs. Subsequently activated STAT5 promotes the expression of LEF1, thus forming a positive feedback loop in TCF1^+^ LEF1^+^ Tregs to promote their competitive fitness.

Tfr Cells Are a Subset of TCF1^+^ aTregs {#S9}
----------------------------------------

Our RNA-seq analysis of fractionated Treg subsets revealed that the expression of *Bcl6* and *Cxcr5* was relatively higher in aTregs than the other two subsets ([Figure 7A](#F7){ref-type="fig"}), suggesting a possible link between TCF1 and Tfr development. In line with this, the expression of Bcl6 gene signature (a set of genes targeted by Bcl6 in Tregs \[[@R40]\]) was over-represented in aTreg, not eTregs ([Figure 7B](#F7){ref-type="fig"}), suggesting that Tfr differentiation is more permissive at the TCF1^+^ aTreg stage. To further evaluate this hypothesis, we did *k*-means clustering and gene ontology (GO) analyses of the transcriptomes of the three Treg subsets, aiming to parse out Treg differentiation stage-associated over- or under-represented genes ([Figure S7A](#SD1){ref-type="supplementary-material"}) and their functional annotations ([Table S5](#SD6){ref-type="supplementary-material"}). Interestingly, "regulation of B cell-mediated immunity" was among the top enriched GO terms in the genes over-represented in TCF1^+^ aTregs (cluster 5) ([Figure 7C](#F7){ref-type="fig"}).

Using Bcl6 and CXCR5 to gate Tfr cells within the Treg pool ([@R53]), we analyzed the abundance of Tfr in each fractioned Treg sub-compartment from peripheral lymphoid organs at steady state. Notably, Tfr cells can only be detected in the TCF1^+^ Treg pool ([Figure 7D](#F7){ref-type="fig"}). About 6% of the TCF1^+^ aTregs exhibited a Tfr phenotype. In other words, \~95% of the Tfr cells were found within the TCF1^+^ aTreg pool, and none of the TCF1^−^ eTregs expressed phenotypic markers of Tfr cells ([Figure 7E](#F7){ref-type="fig"}).

Thus, Tfr cells are a subset of TCF1^+^ aTregs. These data also suggest that the development of Tfr cells occurs at a distinct stage of Treg differentiation, prior to "turning off" TCF1 expression.

TCF1 and LEF1 Are Indispensable for Tfr Generation {#S10}
--------------------------------------------------

Next, we asked whether TCF1 and LEF1 played a role in Tfr differentiation. RNA-seq analysis showed that the expression of both *Bcl6* and *Cxcr5* was reduced in *dKO* versus WT Tregs ([Figure S7B](#SD1){ref-type="supplementary-material"}). Using flow cytometry, we analyzed the abundance of Tfr cells in mice bearing Treg-specific ablation of *Tcf7, Lef1,* or both. Using a gating strategy to show both Tfr and Tfh in the same plot (illustrated in [Figure S7C](#SD1){ref-type="supplementary-material"}), we found that Tfr cells were almost completely abolished in peripheral lymphoid organs of *dKO* mice ([Figures 7F](#F7){ref-type="fig"}, [S7D](#SD1){ref-type="supplementary-material"}, and [S7E](#SD1){ref-type="supplementary-material"}). The percentages of Tfr cells within the pool of Bcl6^hi^ CXCR5^hi^ T cells were reduced about 10-fold. Likewise, the total numbers of Tfr cells were also significantly reduced in *dKO* mice. On the other hand, the total numbers of Tfh cells were significantly increased ([Figure 7F](#F7){ref-type="fig"}), suggesting that Treg-specific ablation of *Tcf7* and *Lef1* altered the balance between Tfr and Tfh. Either *Tcf7* or *Lef1* single knockout exerted partial effects on the reduction of Tfr cells, supporting a redundancy between these two TFs.

We next asked whether the imbalanced Tfr-Tfh ratio in *dKO* mice led to altered germinal center (GC) B cell responses. Indeed, in *dKO* mice even at a relatively young age (7 weeks old), we already observed significantly increased GC B cells (defined as Bcl6^+^ FAS^+^), reflected by both their percentages within the B220^+^TCRβ^−^ pool and the total numbers ([Figures 7G](#F7){ref-type="fig"}, [S7F](#SD1){ref-type="supplementary-material"}, and [S7G](#SD1){ref-type="supplementary-material"}). To further verify the link between Treg-specific *Tcf7/Lef1* ablation and GC B cell responses, we performed immunostainings of splenic frozen sections of 7-week-old *dKO* and littermate control mice. At this age, the GCs in the spleen of control mice were small but detectable. In contrast, in *dKO* mice we found significantly increased GC areas ([Figures 7H](#F7){ref-type="fig"} and [S7H](#SD1){ref-type="supplementary-material"}). As expected, Tfr cells can be readily detected in most GCs in control mice (due to the small sizes of GCs at a young age in control mice, the number of Tfr cells per GC was relatively low). In contrast, the abundance of Tfr cells in each GC of *dKO* mice was significantly reduced, or not detected ([Figure 7I](#F7){ref-type="fig"}), which is consistent with flow cytometric assays showing a dearth of Tfr cells in the *dKO* mice. Using ChIP-PCR, we found that TCF1 bound to the promotor of *Bcl6* in WT Tregs, not *Tcf7*-deficicent T cells ([Figure 7J](#F7){ref-type="fig"}), consistent with the results from a recent study ([@R75]). Thus, TCF1 and LEF1 act redundantly to control Tfr development by regulating Bcl6 expression.

DISCUSSION {#S11}
==========

The phenotypic and functional heterogeneity of Tregs has been increasingly reported ([@R37]; [@R47]). Different regulatory mechanisms, mediated by specific TFs, TCR repertoires, or cytokines, are required for the differentiation, maintenance, and functional specification of each Treg subset ([@R6]; [@R12]). In this study, we report regulatory modules in Tregs that are essential for these cells to maintain immune tolerance. These modules are controlled by TCF1 and LEF1, two TCF family TFs. First of all, TCF1 and LEF1 are required for homeostatic maintenance of CD44^hi^ TCF1^+^ aTreg, a newly defined subset. In the absence of TCF1 and LEF1, the expression and subsequent activation of STAT5 is diminished, causing Tregs unable to compete with activated Tconvs for IL-2. In parallel, the lack of TCF1 and LEF1 also abolishes Tfr generation, leading to unrestrained Tfh and GC B responses, which contributes to the onset of systemic autoimmunity.

The pool of Tregs in peripheral lymphoid organs is composed of CD62L^+^CD44^lo^ and CD62L^−^CD44^hi^ populations, reflecting their state of activation and effector maturation ([@R37]; [@R57]). Our characterizations of TCF1 and LEF1 expression in Tregs revealed that CD62L^−^CD44^hi^ cells can be further divided into two subsets (termed aTreg and eTreg, respectively). aTregs express no or low level of effector Treg-associated TFs (such as IRF4, Blimp1, T-bet, or Gata3) or functional molecules (i.e., ICOS, CTLA4, or IL-10). However, aTregs are not merely an immature or transient subset, because these cells preferentially express both Bcl6 and CXCR5, key genes for Tfr differentiation. This is confirmed by our further analyses including GSEA of DE genes and flow cytometry of fractionated Treg subsets. More interestingly, we find that Tfr cells are almost exclusively derived from the aTreg pool. This is important because it shows that the differentiation of Tfr, a specialized functional subset, occurs at a distinct (TCF1^+^) stage of Treg differentiation, compared to T-bet^+^, STAT3^+^, or other eTreg subsets (which are TCF1^−^). TCF1 acts upstream of *Bcl6* in Tfr generation, consistent with a previous report ([@R75]). Furthermore, our data show that LEF1 also participates in the Tfr generation because Foxp3-Cre-mediated double knockouts of both *Tcf7* and *Lef1* led to almost completely abolished Tfr generation, an effect more profoundly than that by *Tcf7* or *Lef1* single knockout. TCF1 and LEF1 have been reported to promote early differentiation and effector function of Tfh cells, via promoting *Bcl6* expression ([@R8]; [@R72]; [@R74]). Therefore, Tregs acquire a similar TF circuit to differentiate into Tfr, as that by activated Tconvs to undertake Tfh differentiation.

At steady state, TCF1^−^ LEF1^−^ eTregs comprise about 10% of total Treg pool in secondary lymphoid organs. In contrast, in non-lymphoid tissues, the majority of Tregs are TCF1^−^ LEF1^−^. Moreover, tissue Treg gene signatures are largely recapitulated in TCF1^−^ LEF1^−^, but not TCF1^+^ LEF1^+^ Tregs in lymphoid organs (B.-H.Y. and W.F., unpublished data). We thus propose that the small fraction of TCF1^−^ LEF1^−^ Tregs found in lymphoid organs (such as spleen and LNs) could be the precursors of those Tregs accumulated at non-lymphoid tissues. Further studies are needed to determine whether the primary function of these TCF1^−^LEF1^−^ Tregs is to populate tissue Treg pools and regulate tissue homeostasis through participating in immunological or non-immunological processes.

*Tcf7/Lef1 dKO* mice spontaneously develop systemic autoimmunity. However, we found that the total numbers and percentages of bulk Tregs in secondary lymphoid organs were not affected by the ablation of *Tcf7* and *Lef1*. In addition, Tregs can be detected in non-lymphoid tissues of *dKO* mice with comparable abundance to that in WT mice. Furthermore, *dKO* Tregs were equally (or even slightly more) suppressive for the proliferation of effector T cells and DC maturation, indicating that TCF1 and LEF1 are dispensable for Treg suppressive capacity. Then, what causes the onset of autoimmunity in dKO mice? We propose that the deficit of aTreg pool and the lack of Tfr cells in these mice are two plausible causes. We show that TCF1 and LEF1 are essential for maintaining a normal aTreg pool via regulating the expression and subsequent activation of STAT5. TCF1 directly binds to *State* promotor and regulates its expression. In line with this, TCF1^+^ Tregs express higher levels of *Stat5a* and *Stat5b* and more potently respond to IL-2. Conversely, the deficiency of *Tcf7* and *Lef1* remarkably reduces STAT5 expression in Tregs. The expression level of total STAT5 protein in Tregs is correlated with its activation (pSTAT5). However, the ratio of pSTAT5/STAT5 was not affected by *Tcf7/Lef1* depletion, suggesting that TCF1 primarily influences the expression, not the activation of STAT5. Interestingly, a constitutively activated form of STAT5 promotes the expression of LEF1 in Tregs but not Tconv cells. Thus, our data support a positive feedback loop of TCF1-STAT5-LEF1 in Treg homeostatic maintenance. Of note, Liu et al. reported that pSTAT5^+^ Tregs formed clusters with self-antigen activated IL-2-producing T cells and were essential for suppressing incipient autoimmunity ([@R39]). We predict that the population of pSTAT5^+^ cells described by Liu et al. is overlapped with TCF1^+^ aTregs. Indeed, we found that TCF1^+^ Tregs were enriched in the T cell zones, which is also in line with another study showing that central (resting) Tregs gain more access to paracrine IL-2 than effector Tregs ([@R56]). Together, our data reinforce the role of pSTAT5^+^ Tregs in keeping autoimmunity in check and highlight the importance of TCF1 and LEF1 as two upstream regulators.

It has been reported that thymic Tregs are derived from CD25^+^ Foxp3^−^ precursors in a STAT5-dependent manner ([@R5]; [@R36]). However, we found that thymic Treg profile was comparable between *dKO* and WT mice, suggesting that the deficiency of *Tcf7* and *Lef1* does not alter Treg development in the thymus. Interestingly, during the revision of this manuscript, Owen et al. reported that a second developmental program involving CD25^−^ Foxp3^lo^ Treg precursors also contributed to the generation of thymic Tregs with high efficiency ([@R46]). Indeed, we found that the expression of TCF1 in CD25^−^ Foxp3^lo^ Treg precursors was lower than that in CD25^+^ Foxp3^−^ precursors, suggesting that CD25^−^ Foxp3^lo^ precursor-mediated thymic Treg development is less dependent on TCF1 ([Figure S5A](#SD1){ref-type="supplementary-material"}, right). We propose that CD25^−^ Foxp3^lo^ precursors may compensate for the defect of thymic Tregs caused by *Tcf7/Lef1* deficiency. In addition, it would be also interesting to determine whether CD25^−^ Foxp3^lo^ thymic Treg precursors can directly populate the eTreg pool in peripheral organs. Though continuous thymic output and increased proliferation rate may partially rescue bulk Treg homeostasis in *dKO* mice in the periphery, the aTreg pool cannot be restored. A more deleterious consequence of aTreg defect is the lack of Tfr generation, causing unrestrained Tfh and GC B responses. Of note, while the size of eTreg pool is significantly increased and their suppressive capacity remains intact in *dKO* mice, the early onset of autoimmune diseases in these mice suggests that eTregs alone are not sufficient to keep autoimmunity fully in check. In other words, our data support the importance of the "wholeness" of Treg's diverse subsets and functions to prevent the onset of autoimmune diseases.

We show that Tfr cells are almost exclusively derived from the TCF1^+^ aTreg pool, which relies on IL-2/STAT5 signaling for their maintenance. It has been reported that Tfr cells downregulate CD25 ([@R4]; [@R50]). Further studies by Wing et al. revealed that Tfr cells can be divided into CD25^+^ and CD25^−^ subsets ([@R70]), and the authors proposed a "two-step" model for Tfr development ([@R71]). Thus, our data suggest that the axis of TCF1-STAT5 plays a more critical role in the initiation, not the maturation, of Tfr lineage. TCF1 and LEF1 promote the development and function of Tfh cells ([@R8]; [@R72]; [@R74]).

Our findings are in line with a previous study showing that β-catenin activation did not alter Treg function but instead improved their survival ([@R14]). Conversely, the activation of β-catenin has also been reported to negatively impact thymic Treg development ([@R2]) or Treg suppressive function ([@R67]). In those studies, TCF1 was implicated as a downstream regulator. During the revision of this manuscript, another study was published showing that Treg-specific β-catenin stabilization led to lethal autoimmunity in mice with dysfunctional Treg phenotype ([@R61]). Interestingly, they found that β-catenin stabilization was associated with human IFN-γ-secreting Tregs, which also expressed a relatively higher level of *TCF7*. While these discrepancies could be due to the differences of experimental settings or methods used to examine the functions of Tregs, it is also possible that excessive activation of β-catenin and downstream TCF1 disturbs Treg homeostasis, likely causing abnormalities within the eTreg compartment, as our data suggest that the downregulation of TCF1 and LEF1 is a prerequisite for eTreg differentiation. Indeed, we find that the retroviral transduction of *Tcf7* in *dKO* Treg can reconstitute the aTreg pool but fails to rescue eTregs, owing to the constitutive expression of TCF1 in transduced cells.

Genome-wide association studies (GWASs) have found that *TCF7* polymorphisms are associated with the risk of human autoimmune diseases, T1D ([@R10]; [@R18]; [@R30]), and systemic lupus erythematosus (SLE) ([@R43]; [@R62]). Altered Treg homeostasis and function caused by mutant *TCF7* or *LEF1* may contribute to the development of these autoimmune disorders. As demonstrated in animal models in this study, compromised Treg competitive fitness and defects of aTreg maintenance and associated Tfr generation could be the underlying mechanisms.
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CONTACT FOR REAGENT AND RESOURCE SHARING {#S13}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Wenxian Fu (<w3fu@ucsd.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Mice {#S15}

C57BL/6J (B6), *Foxp3^YFP-Cre^* ([@R52]), B6/*Rag1*^−/−^, B6/*Tcrα*^−/−^ and B6/CD45.1 mice were purchased from the Jackson Laboratory. *Foxp3^Thy1.1^* ([@R38]), *Tcf7^fl/fl^* and *Lef1^fl/fl^* ([@R58]; [@R78]) and *Tcf7^GFP^*([@R8]; [@R76]) mice have been described. *Tcf7^fl/fl^* and *Lef1^fl/fl^* mice were crossed with *Foxp3^YFP-Cre^* to generate *Foxp3^Cre^Tcf7^fl/fl^* (termed *Tcf7KO*), *Foxp3^Cre^Lef1^fl/fl^* (*Lef1KO*), *Foxp3^Cre^Tcf7^fl/fl^Lef1^fl/fl^* (*dKO*), *Foxp3^Cre/wt^Tcf7^fl/fl^Lef1^fl/fl^*, and littermate control mice, respectively. *Tcf7^GFP^* mice were crossed with *Foxp3^Thy1.1^* to generate *Foxp3^Thy1.1^Tcf7^GFP/wt^*.

Both female and male mice were used. There was no sex-bias in the profile of peripheral Tregs. However, in one set of experiments, we use female heterozygous mice (i.e., *Foxp3^Cre/wt^Tcf.^7fl/fl^ Lef1^fl/fl^* and *Foxp3^Cre/wt^Tcf7^wt/wt^ Lef1^wt/wt^*) to examine Treg phenotype under non-inflammatory conditions. 6-9-week-old mice were used unless specified in the text or figure legends.

### Study Approval {#S16}

All mice were housed under the specific pathogen free (SPF) conditions in our animal facility at University of California, San Diego, in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee.

METHOD DETAILS {#S17}
--------------

### Immune cell isolation {#S18}

Single-cell suspensions of lymphoid organs were prepared by mechanic disruption through 100-μm strainers (Thermo Fisher Scientific). Red blood cells were lysed using Ammonium-Chloride-Potassium (ACK) buffer (Lonza, Walkersville, MD). Small intestinal and colonic lamina propria cells were prepared as previously described ([@R79]). Briefly, the intestine was physically emptied, opened longitudinally and sliced into 0.2--0.5 cm pieces, followed by incubating in 20 mL PBS containing 5 mM EDTA at 37°C on a shaker (200 x rpm) for 15 min. The intestine fragments were further digested in 20 mL RPMI 1640 containing 2% FBS, Collagenase D (1 mg/ml) (Roche) and DNase I (0.1 mg/ml) (Sigma-Aldrich) at 37°C on a shaker (200 x rpm) for 45 min. Samples were collected by passing through 70 μm cell strainers. The cells were then purified using a 40/80% Percoll (GE Healthcare Life Science) gradient by centrifugation (900 x g, 20 min, no break at room temperature). The interphase was harvested and washed. The cells were resuspended in PBS containing 0.2% bovine serum albumin or medium containing fetal calf serum before extra/intracellular staining.

### Flow cytometry {#S19}

The antibodies used in this study were listed in the [Key Resources Table](#T1){ref-type="table"}. All stainings began by an incubation with anti-CD16/32 (2.4G2, Tonbo). Dead cells were excluded from analyses by using LIVE/DEAD fixable Aqua dead cell stain kit (Invitrogen) according to the manufacturer's instructions. Surface staining was performed in PBS containing 0.2% BSA at 4°C. Intracellular staining was performed using Foxp3/transcription factor staining buffer set (eBioscience) according to the manufacturer's instruction. For analyzing retrovirus transduced GFP^+^ cells, the cells were fixed with 0.8% PFA for 10 mins at 37°C and followed by intracellular staining using Foxp3/transcription factor staining buffer set. For intracellular IFNγ and IL-17A detection, the cells were cultured in complete medium in the presence of phorbol myristate acetate (PMA), Ionomycin (Signa-Aldrich) at 37°C for 4 hr. Brefeldin A (BioLegend) was added 2 hr prior to cell harvest. Samples were acquired with a BD LSRFortessa or LSRFortessa X20 (BD) and analyzed with FlowJo software (FlowJo, LLC).

### RNA-sequencing and data analysis {#S20}

Tregs were first enriched by magnetic positive selection for Thy1.1 (MACS) from pooled spleens and LNs of *Foxp3^Thy1.1^Tcf7^GFP^* mice and then sorted with BD Aria2. For *dKO* and WT Treg isolation, CD4^+^ cells were first enriched by magnetic depletion (STEMCELL) from pooled spleens and LNs of *Foxp3^YFP-cre/wt^Tcf7^fl/fl^Lef1^fl/fl^* or *Foxp3^YFP-cre/wt^Tcf7^wt/wt^Lef1^wt/wt^* mice, respectively. RNA was extracted using the RNeasy Plus Mini Kit (QIAGEN) according to the manufacturer's instructions. Quality and integrity of total RNA were controlled on Tapestation (Agilent Technologies). cDNA library was prepared using TruSeq® Stranded mRNA LT - Set A (Illumina) according to the manufacturer's instructions. Sequencing was conducted on Illumina Hiseq 4000 (SR50 or SR75) at the UCSD IGM Genomics Center. Fastq files from sequencing experiments were mapped to the mouse GRCm38 genome using default parameters for STAR ([@R15]). Next, we performed gene differential expression analysis using Cuffdiff ([@R66]) and the *R* package Extraction of Differential Gene Expression (EDGE) ([@R59]). Principle component analysis (PCA), Gene Set Enrichment Assay (GSEA) ([@R60]), and K-means clustering analysis were performed using the modules embedded in GenePattern software package ([@R49]).

### *In vitro* Treg suppression assay {#S21}

CD11c^+^ splenic DCs were enriched by MACS from spleens treated with Liberase TL (Roche). T responder cells (Tresp) and WT Tregs were FACS sorted from spleen and LNs of male *Foxp3^Y/cre^Tcf7^wt/wt^Lef1^wt/wt^* mice. *dKO* Tregs were sorted from male *Foxp3^Y/cre^Tcf7^fl/fl^Lef1^fl/fl^* mice. Tresp cells were prelabeled with CTV (Molecular Probes, Invitrogen) and co-cultured with DCs and Tregs at the indicated ratio in the presence of 0.5 ug/ml soluble anti-CD3 antibody and analyzed on day 4 by flow cytometry for CTV dilution and DC maturation.

### Cell line {#S22}

293T cells were purchased from ATCC (ATCC® CRL-3216) and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% Fetal Bovine Serum.

### Retroviral transduction {#S23}

Viruses were prepared by transfecting 293T cells with retroviral expression plasmids (pMIG, MSCV-IRES-GFP) encoding GFP only, *Tcf7* ([@R7]), or *caSTAT5* ([@R28]). Retrovirus-containing supernatants were collected and concentrated by full speed centrifugation at 4°C overnight and resuspended in the desired volume of complete medium with 1.6 ug/ml polybrene (Sigma-Aldrich). CD4^+^ cells were enriched from spleens and lymph nodes of indicated mice by magnetic depletion with mAbs against CD8α, CD11b, CD11c, CD19, TCRγδ, CD119 and NK1.1. The purity of enriched CD4^+^T cells was \> 95%. These cells were activated with plate-bound anti-CD3 (2.5 μg/ml), soluble anti-CD28 (2.5 μg/ml) and 200 U/ml of recombinant human IL-2 (PeproTech) in complete culture medium (RPMI 1640 supplemented with 10% fetal calf serum, 2 mM L-Glutamine, 100 U/ml penicillin/streptomycin, non-essential AA sup. and 50 μM 2-Mercaptoethanol). After 40 hr, activated T cells were spin-infected (400 x g, 32°C, 1 hr) with retrovirus supernatants prepared as above. For *in vitro* assay, transduced T cells were cultured for an additional 72 hr and analyzed by FACS. For *in vivo* transfer assays, transduced cells were washed twice with 1x PBS and transferred into *Rag1*^−/−^ or *Tcrα*^−/−^ mice.

### Adoptive cell transfer {#S24}

CD4^+^ T cells were enriched from the spleens of *Foxp3^Cre^* (WT) or *Tcf7^fl/fl^Lef1^fl/fl^;Foxp3^cre^* (*dKO*) mice by MACS (Miltenyi). 2 million cells were transferred *i.p.* into *Tcrα*^−/−^ mice. For the co-transfer experiments, CD4^+^ T cells from *CD45.1/Foxp3^Cre^* and *CD45.2/Foxp3^Cre^* mice were mixed at 3:1 before transferring into *Tcrα*^−/−^ mice; Similarly, CD4^+^ T cells from *CD45.1/Foxp3^Cre^* and *CD45.2/Foxp3^Cre^Tcf7^fl/fl^Lef1^fl/fl^* mice were mixed at 3:1 before transferring into *Tcrα*^−/−^ mice.

### *Ex vivo* assays of total STAT5 protein and pSTAT5 by flow cytometry {#S25}

pLN and mLN were directly meshed into BD Cytofix/Cytoperm (BD), incubated for 1 hr at room temperature. Single-cell suspensions were then washed and permeabilized with 90% methanol on ice for 30 min. Surface and intracellular staining were performed using Foxp3/transcription factor staining buffer set (eBioscience) according to the manufacturer's instruction.

### *In vitro* STAT5 phosphorylation assays {#S26}

Total splenocytes (1 × 10^6^) first rested in complete RPMI1640 medium for 30 minutes and were then incubated with indicated human IL-2 concentration for 15 min at 37°C. After that, cells were fixed with paraformaldehyde (0.8%) for 10 minutes at 37°C. Fixed cells were permeabilized with ice-cold methanol for 30 minutes and were stained with anti-phospho-STAT5 (clone 47/Stat5\[pY694\]; BD Biosciences) and other surface or intracellular antibodies for 1 hour at room temperature.

### Enzyme-linked immunosorbent assay (ELISA) {#S27}

Sera IgG and IgE were quantitated using mouse uncoated ELISA Kits (Thermo Fisher) according to manufacturer's instructions. The titters of Ig subclasses were measured using Ig isotyping mouse uncoated ELISA Kit (Thermo Fisher).

### Chromatin immunoprecipitation {#S28}

Tregs were isolated by magnetic separation from pooled spleens and LNs of *Foxp3^Thy1.1^* mice and CD4^+^T cells from *CD4^Cre^*;*Tcf7^fl/fl^* mice. Collected cells were fixed with freshly prepared 1% methanol-free formaldehyde at room temperature for 5 min. Chromatin shearing was performed using truChIP Chromatin Shearing Kit with Formaldehyde (Covaris) on E220 (Covaris) according to the manufacturer's manual. Chromatin immunoprecipitation was performed as previously described ([@R3]). Briefly, fragmented chromatin was incubated with protein A dynabeads (Invitrogen) pre-coupled with rabbit anti-TCF1 sera at 4°C overnight. Beads were then washed using ice-cold IP buffer and ice-cold TE buffer. 10% (w/v) Chelex 100 slurry was used to reverse crosslink at 100°C for 10 mins. The primers for PCR were listed in the [Key Resources Table](#T1){ref-type="table"}.

### Immunostaining and histology {#S29}

Tissue samples were snap-frozen in optimum cutting temperature (O.C.T., Fisher Scientific, Houston, TX). Cryo-sections of tissue sections (6 μm) were cut, fixed with pre-cold acetone for 20 min and blocked with normal rat serum. The following mAbs were used in different combinations as indicated in the figure legends: anti-B220 (RA3-6B2), anti-GL7 (GL7), anti-Foxp3 (FJK-16 s), anti-CD4 (RM4-5). Nuclei were stained with DAPI (4',6-Diamidino-2--28 phenylindole dihydrochloride) (Invitrogen). Images were acquired on ZEISS AXIOSCAN Z1 SLIDE SCANNER (Zeiss), and were processed with Zen (Blue edition). For histology, the indicated organs were removed and fixed with 10% formalin solution. Fixed tissue blocks were transferred to 70% ethanol, paraffin-embedded, sectioned, stained with hematoxylin and eosin and scanned on ZEISS AXIOSCAN Z1 SLIDE SCANNER.

### Western blot for autoantibody detection {#S30}

Pancreas, salivary glands and kidney from female *Rag1*^−/−^mice were homogenized (VWR200 Homogenizer, VWR) on ice in a buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100,1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, and a protease inhibitor cocktail (Thermo Scientific). The homogenates were centrifuged at 12,000 x g per minute for 10 min, and the supernatants were mixed with a 4 x Laemmli Sample Buffer (Bio-Rad) and boiled for 5 min at 100°C. The extracts were separated by 10% SDS-PAGE gel and electrophoretically transferred onto a PVDF membrane (Bio-Rad). The membranes were blocked with PBS (VWR) containing 0.1% Tween-20 (Fisher Scientific) and 5% nonfat milk (Bio-Rad) for 1 h and assembled in a Mini-PROTEAN II Multiscreen Apparatus (Bio-Rad) and incubated overnight with 1:600 dilution of sera collected from *dKO* or control mice. After washing three times with PBST, the bound antibodies were reacted with Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG (1:5,000, Jackson ImmunoResearch Laboratories) for 1 h, washed with PBST for three times, revealed with Clarity Western ECL Substrate (Bio-Rad) and autoradiography.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

### Statistical Analysis {#S32}

Statistical analysis was conducted using GraphPad Prism 6 software (GraphPad Software). Data are presented as mean ± s.e.m. Statistical significance was calculated by the Student's t test with a 95% confidence interval. *P values* of 0.05 or less were considered statistically significant. *P values* for gene signature distribution were calculated using the Chi-square (χ^2^) test. Further detailed information of the number (n) of repeated experiments is indicated in the figure legends.

DATA AND SOFTWARE AVAILABILITY {#S33}
------------------------------

Data source: The accession number for RNA-seq reported in this paper is GEO: GSE117726.
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![Gradient Expression of TCF1 and LEF1 Distinguishes Peripheral Treg into Distinct Subsets\
(A) Flow cytometric analysis of the expression of CD44, CD62L, and TCF1 in Tregs from the spleens of 6- to 8-week old B6 mice.\
(B) Histograms summarize the MFIs of TCF1, CD62L, and CD44 in the R1 (blue), R2 (green), and R3 (red) subsets, as depicted in (A).\
(C) The proportions of the R1, R2, and R3 Treg subsets in the spleen, pLNs, and mLNs.\
(D) Flow cytometric analysis of TCF1 expression in splenic Tregs of adult (11 weeks old) and aged (55 weeks old) mice.\
(E) Flow cytometric analysis of the expression of LEF1 and CD62L in cells prepared as in (A).\
The data are representative of n = 3 independent experiments with n = 3--4 mice in each group. Shown are mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; n.s., non-significant (two-tailed unpaired Student's t test). wk, week; Spl, spleen; pLN, peripheral (cervical, axillary, brachial, and inguinal) lymph nodes; mLN, mesenteric lymph nodes.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1532291-f0001){#F1}

![TCF1^+^and TCF1^−^Tregs Have Distinct Transcriptomes\
(A) Principle-component analysis (PCA) of the transcriptomes of the R1, R2, and R3 Treg subsets as defined in [Figure 1](#F1){ref-type="fig"}.\
(B) Volcano plots showing the comparisons among the three Treg subsets. The T cell activation gene signature (red open circles) was superimposed onto each plot. The numbers of T cell activation signature genes that were over- or under-represented in each comparison and the p values (by χ^2^ test) were shown.\
(C and D) Heatmaps (row normalized) depicting the expression of the selected transcription factor (C) and key functional molecules (D) in the R1, R2, and R3 Treg subsets. Genes were ranked and clustered according to their correlation to *Tcf7* (C) or *Icos* (D). r^2^, correlation coefficient; min, lowest expression in each row; max, highest expression in each row.\
(E and F) Flow cytometric analysis of surface molecule: ICOS, CD103, and KLRG1 (E) and transcription factors: IRF4 and Blimp1 (F) in the R1, R2, and R3 Treg subsets.\
(G) Graphic summary illustrating the revised model of the Treg pool in peripheral lymphoid organs.\
The data are representative of one experiment with n = 2 replicates for each Treg subsets (A--D) or n = 3 independent experiments (E and F). Shown are mean ± SEM (E and F). p values in (B) were calculated using the chi-square (χ^2^) test. p values in (E) and (F) were calculated using the two-tailed unpaired Student's t test. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001, n.s., non-significant.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Tables S1](#SD2){ref-type="supplementary-material"}, [S2](#SD3){ref-type="supplementary-material"}, and [S3](#SD4){ref-type="supplementary-material"}.](nihms-1532291-f0002){#F2}

![Treg-Specific Ablation of TCF1 and LEF1 Leads to Spontaneous Development of Systemic Autoimmunity\
(A) Representative images of spleen and pLNs from the mice with indicated genotypes. (right) The total numbers of live cells in the pLNs and spleen from the indicated mice.\
(B) H&E staining of thyroid glands, salivary glands, lung, small intestine, and colon from *Tcf7^wt/wt^Lef1^wt/wt^;Foxp3^Cre^* (WT) and *Tcf7^fl/fl^Lef1^fl/fl^;Foxp3^Cre^* (*dKO*) mice. Green arrows are pointing to the immune infiltrations.\
(C) Flow cytometric analysis of the percentages and numbers of IFN-γ-producing CD4^+^ cells from pLNs of mice as indicated.\
(D) Flow cytometric analysis of the percentages and numbers of IL-17A-producing CD4^+^ cells from the pLNs of mice as indicated.\
(E) ELISA of the IgE (left) and IgG (right) production in the serum of mice with indicated genotypes.\
(F) Western blot of homogenized tissue digestions (kidney, pancreas, liver, stomach, thyroid glands, and salivary glands) from female *Rag1*^−/−^ mice with the sera from WT or *dKO* mice.\
The data are representative of n = 3 independent experiments with n = 3--4 mice in each group. Shown are mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, n.s., non-significant (two-tailed unpaired Student's t test). Scale bar, 200 μm.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1532291-f0003){#F3}

![TCF1 and LEF1 Are Dispensable for Treg's Suppressive Capacity\
(A) Schematic diagram of experimental settings.\
(B) Representative histograms of cell trace violet (CTV) dilution in indicated groups (left) and statistical data of Treg-mediated suppression on Tresp cells (right).\
(C) Representative histograms of CD80 expression in DCs in indicated groups (top) and statistical data of Treg-mediated suppression on CD80 expression at indicated ratios (bottom).\
(D) Representative histograms of CD86 expression in DCs in indicated groups (top) and statistical data of Treg-mediated suppression on CD86 expression at indicated ratios (bottom).\
(E) Representative histograms of CTLA4 expression in DCs in WT (left) and *dKO* Tregs and statistical data (right).\
The data are representative of n = 2 independent experiments with pooled n = 3 mice in each group. Shown are mean ± SEM. \*p \< 0.05; \*\*p \< 0.01; n.s., non-significant (two-tailed unpaired Student's t test).\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1532291-f0004){#F4}

![The Deficiency of TCF1 and LEF1 Leads to a Severe Reduction of aTregs\
(A) Expression-expression plot of transcriptomes of WT Tregs isolated from *Foxp3^YFP-Cre/wt^Tcf7^wt/wt^Lef1^wt/wt^* mice and *dKO* Tregs from *Foxp3^YFP-Cre/wt^Tcf7^fl/fl^Lef1^fl/fl^* mice. Superimposed is the bulk Treg gene signature. Numbers depict the Treg signature genes over- or under-represented in *dKO* versus WT samples.\
(B) GSEA analysis of the "hallmark" gene sets deposited in MSigDB. Both p values and FDR q values were shown. NES, normalized enrichment score.\
(C) Volcano plots showing the comparisons between WT and *dKO* Tregs. The T cell activation gene signature (red) was superimposed. The numbers of T cell activation signature genes that were over- or under-represented in each comparison and the p value (by χ2 test) were shown.\
(D) The proliferation of WT and *dKO* Tregs in Spleen, pLNs, and mLNs measured by Ki67 staining.\
(E) Row-normalized heatmap of the expression of bulk Treg signature genes across r-, a-, and e-Treg subtypes (left). Superimposing each sub-cluster defined on the left to the FC plot comparing *dKO* versus WT Tregs (right).\
(F) The percentages of Treg subsets in *dKO* and WT littermate controls using the gating strategy defined in [Figure S5E](#SD1){ref-type="supplementary-material"}.\
(G) Representative fluorescence-activated cell sorting (FACS) plots showing the gating strategy and the compositions of Treg pool based on the expression of Helios, ICOS, and CD62L in WT and *dKO* mice (top). The percentages and numbers of each Treg subsets in Helios^+^ Treg compartment (bottom).\
(H) The effect of retroviral transduction of *Tcf7* on Treg differentiation *in vitro*. Experimental settings (top) and statistical data of Treg subsets in control (*pMIG*) and Tcf7-transduction groups (bottom).\
The data are representative of one experiment with n = 2 replicates for each Treg subsets (A--C and E) or n = 2 (F--H), n = 3 (D) independent experiments. n = 3 mice in each group. Shown are mean ± SEM. p values in (C) were calculated using the chi-square (χ2) test. p values in (D) and (F)--(H) were calculated using the two-tailed unpaired Student's t test. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001, n.s., non-significant.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1532291-f0005){#F5}

![TCF1 and LEF1 Are Required for Treg's Competitive Fitness by Regulating STAT5 Expression and Activation\
(A) The percentages of CD25 expression in TCF1^+^ and TCF1^−^ Tregs.\
(B) *In vitro* pSTAT5 assays in TCF1 ^+^ and TCF1^−^ Tregs, stimulated with IL-2 at various concentrations.\
(C) GSEA analysis revealing that IL-2/STAT5 signaling was significantly under-represented in *dKO* Tregs. NES, normalized enrichment score.\
(D) *In vitro* pSTAT5 assays in *dKO* and WT Tregs, stimulated with IL-2 at various concentrations. (left) The percentages of pSTAT5; (right) the MFI of pSTAT5 (gated on pSTAT5^+^).\
(E) *Ex vivo* analysis of total STAT5 protein and pSTAT5 in *dKO* and WT Tregs. Representative FACS plots (top). Percentages of total STAT5 protein and pSTAT5, and the ratios of pSTAT5/total STAT5, respectively (bottom).\
(F) ChIP-PCR analysis showing enriched binding of TCF1 to *Stat5b* promoter.\
(G) *In vivo* Treg survival assays. Splenic CD4^+^ T cells were isolated from WT (*Foxp3^Cre^*) or *dKO* mice, *i.p.* transferred into *Tcrα*^−/−^ mice and analyzed 5 weeks later. FACS plots and statistical data show the percentages of Tregs reconstituted from transferred donor cells.\
(H) *In vivo* Treg survival assays under competitive conditions. Splenic CD4^+^ T cells were isolated from CD45.1 WT (*Foxp3^Cre^*), CD45.2 WT (*Foxp3^Cre^*), or CD45.2 *dKO* mice, mixed at a ratio of 3:1 between CD45.1 versus CD45.2 donor cells, *i.p.* transferred into *Tcrα*^−/−^ mice and analyzed 5 weeks later. FACS plots and statistical data show the percentages of Tregs reconstituted from each type of donor cells in spleen, pLNs, and mLNs.\
(I) Schematic diagram showing that splenic CD4^+^ T cells from WT or *dKO* mice were MACS enriched and transduced with retroviruses expressing *Tcf7*, or *caSTAT5*, i.p. transferred into *Tcrα*^−/−^ mice and analyzed 3 weeks later (top). Representative FACS plots and statistical data showing the reconstitution of Tregs from different inputs as described in the inset legend (middle). The MFIs of TCF1 and LEF1 in Tregs from the conditions as described in the inset legend (bottom). The data are representative of n = 3 (A, B, D, and E) and n = 2 (F, G, and I) independent experiments and one experiment with n = 2 replicates for each Treg subsets (C) or one experiment with n = 3 mice in each group (H). n = 4--6 mice in each group. Shown are mean ± SEM. The p values were calculated using two-tailed unpaired Student's t test. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. RV, retrovirus; Ctl, control; wk, week.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1532291-f0006){#F6}

![TCF1 and LEF1 Redundantly Control Tfr Generation and Germinal Center B Cell Responses\
(A) The expression of *Bcl6* (left) and *Cxcr5* (right) detected by RNA-seq in the three Tregs.\
(B) GSEA analysis revealing that Bcl6 gene signature was enriched in TCF1^+^ aTregs not TCF1^−^ eTregs. NES, normalized enrichment score.\
(C) Gene ontology (GO) annotations of the over-represented genes in TCF1^+^ aTregs identified by *k*-means clustering analysis (see [Figure S7A](#SD1){ref-type="supplementary-material"} for detail).\
(D) Flow cytometric analysis of Bcl6 and CXCR5 in the three Treg subsets.\
(E) Superimposing Tfr cells onto the bulk Treg plot (TCF1 versus CD62L). Inset numbers show the percentages of Tfr cells fell into each quadrant.\
(F) Flow cytometric analysis of Foxp3 expression in CD4^+^ Bcl6^+^ CXCR5^+^ T cells from spleen of indicated mice (left). The percentages and numbers of Tfr and Tfh cells (right).\
(G) Flow cytometric analysis of the expression of Bcl6 and FAS expression in CD4^−^ B220^+^ cells in the spleen of indicated mice.\
(H) Immunofluorescence staining of splenic frozen sections from *Tcf7^wt/wt^Lef1^wt/wt^; Foxp3^Cre^* (WT) and *Tcf7^fl/fl^Lef1^fl/fl^;Foxp3^Cre^* (*dKO*) mice. Statistical data show the intensities of GL7 staining in each individual B220^+^ follicles normalized by the area of B cell follicles.\
(I) Immunofluorescence staining of samples as in (H) with Foxp3, GL7, and CD4. Arrows in the top panel (WT) depicting Tfr cells. The numbers of Foxp3^+^ T cells within each individual GCs was counted and then normalized by the size of the GC area.\
(J) ChIP-PCR analysis showing enriched binding of TCF1 to Bcl6 (upstream −500) in WT Tregs. Splenic CD4^+^ T cells from *Tcf7^fl/fl^*CD4^Cre^ mice were used as negative control to show the background of TCF1 binding.\
The data are representative of n = 2 replicates for each Treg subsets (A--C); n = 3 independent experiments (D, E, and J) or n = 2 experiments with n = 3--4 mice in each group (F--I). The statistic calculation in (B) was false discovery rate (FDR) q value. Shown are mean ± SEM. The p values in (A, D, and F--I) were calculated using the two-tailed unpaired Student's t test. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. Scale bars, 100 μm (H) and 50 μm (I).\
See also [Figure S7](#SD1){ref-type="supplementary-material"} and [Tables S4](#SD5){ref-type="supplementary-material"} and [S5](#SD6){ref-type="supplementary-material"}.](nihms-1532291-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                     SOURCE                     IDENTIFIER
  ----------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------
  Antibodies                                                                                         
  Rat monoclonal anti-CD4 (GK1.5) FITC                                    BioLegend                  Cat\#100406; RRID:AB_312691
  Rat monoclonal anti-CD4 (GK1.5) PE                                      BioLegend                  Cat\#100408; RRID:AB_312693
  Rat monoclonal anti-CD4 (GK1.5) PE/Cy7                                  TONBO                      Cat\#60-0041-U100; RRID:AB_2621828
  Rat monoclonal anti-CD4 (RM4-5) APC                                     BioLegend                  Cat\#100516; RRID:AB_312718
  Rat monoclonal anti-CD4 (RM4-5) BV605                                   BioLegend                  Cat\#100548; RRID:AB_2563054
  Rat monoclonal anti-CD8a (53-6.7) APC                                   TONBO                      Cat\#20-0081-U100; RRID:AB_2621550
  Rat monoclonal anti-CD8a (53-6.7) PE                                    TONBO                      Cat\#50-0081-U500; RRID:AB_2621741
  Rat monoclonal anti-CD8a (53-6.7) PE/Cy7                                eBioscience                Cat\#25-0081-81; RRID:AB_469583
  Rat monoclonal anti-CD8a (53-6.7) Biotin                                BioLegend                  Cat\#100704; RRID:AB_312743
  Rat monoclonal anti-CD8a (53-6.7) APC/Cy7                               BioLegend                  Cat\#100714; RRID:AB_312753
  Rat monoclonal anti-CD11b (M1/70) BV605                                 BioLegend                  Cat\#101237; RRID:AB_11126744
  Rat monoclonal anti-CD11b (M1/70) PE                                    BioLegend                  Cat\#101208; RRID:AB_312791
  Rat monoclonal anti-CD11b (M1/70) Biotin                                BioLegend                  Cat\#101204; RRID:AB_312787
  American Hamster monoclonal anti-CD11c (N418) Biotin                    BioLegend                  Cat\#117304; RRID:AB_313773
  American Hamster monoclonal anti-CD11c (N418) PE                        BioLegend                  Cat\#117308; RRID:AB_313777
  Rat monoclonal anti-CD19 (6D5) Biotin                                   BioLegend                  Cat\#115504; RRID:AB_313639
  Rat monoclonal anti-CD19 (6D5) PE                                       BioLegend                  Cat\#115508; RRID:AB_313643
  Rat monoclonal anti-CD25 (PC61) Biotin                                  BioLegend                  Cat\#102004; RRID:AB_312853
  Rat monoclonal anti-CD25 (PC61) PE                                      BioLegend                  Cat\#102008; RRID:AB_312857
  Rat monoclonal anti-CD25 (PC61) PE/Cy7                                  BioLegend                  Cat\#102016; RRID:AB_312865
  Rat monoclonal anti-CD25 (PC61) PerCP-Cy5.5                             BioLegend                  Cat\#102030; RRID:AB_312865
  Rat monoclonal anti-CD44 (IM7) APC                                      BioLegend                  Cat\#103012; RRID:AB_312963
  Rat monoclonal anti-CD44 (IM7) FITC                                     BioLegend                  Cat\#103006; RRID:AB_312957
  Rat monoclonal anti-CD44 (IM7) PE                                       BioLegend                  Cat\#103008; RRID:AB_312959
  Mouse monoclonal anti-CD45.1 (A20) PerCP/Cy5.5                          BioLegend                  Cat\#110728; RRID:AB_893346
  Mouse monoclonal anti-CD45.2 (104) APC/Cy7                              BioLegend                  Cat\#109824; RRID:AB_830789
  Rat monoclonal anti-CD45R (RA3-6B2) APC                                 TONBO                      Cat\#20-0452-U025; RRID:AB_2621574
  Rat monoclonal anti-CD45R (RA3-6B2) PerCP/Cy5.5                         BioLegend                  Cat\#103236; RRID:AB_893354
  Rat monoclonal anti-CD45R (RA3-6B2) Biotin                              BioLegend                  Cat\#103204; RRID:AB_312989
  Rat monoclonal anti-CD45RB (C363-16A) PerCP/Cy5.5                       BioLegend                  Cat\#103314; RRID:AB_2284707
  Rat monoclonal anti-CD49b (DX5) Biotin                                  BioLegend                  Cat\#108904; RRID:AB_313411
  Rat monoclonal anti-CD62L (MEL-14) APC                                  BioLegend                  Cat\#104412; RRID:AB_313099
  Rat monoclonal anti-CD62L (MEL-14) PE                                   BioLegend                  Cat\#104407; RRID:AB_313094
  Rat monoclonal anti-CD62L (MEL-14) PE/Cy7                               BioLegend                  Cat\#104418; RRID:AB_313103
  Armenian Hamster monoclonal anti-CD69 (H1.2F3) PerCP/Cy5.5              BioLegend                  Cat\#104522; RRID:AB_2260065
  Rat monoclonal anti-CD73 (TY/11.8) Biotin                               BioLegend                  Cat\#127203; RRID:AB_1089063
  Armenian Hamster monoclonal anti-CD80 (16-10A1) Al488                   BioLegend                  Cat\#104716; RRID:AB_492822
  Rat monoclonal anti-CD86 (GL-1) APC/Cy7                                 BioLegend                  Cat\#105029; RRID:AB_2074993
  Mouse monoclonal anti-CD90.1 (OX-7) Biotin                              BioLegend                  Cat\#202510; RRID:AB_2201417
  Mouse monoclonal anti-CD90.1 (OX-7) PE                                  BioLegend                  Cat\#202524; RRID:AB_1595524
  Mouse monoclonal anti-CD90.1 (OX-7) PerCP/Cy5.5                         BioLegend                  Cat\#202516; RRID:AB_961437
  Mouse monoclonal anti-CD95 (SA367H8) FITC                               BioLegend                  Cat\#152606; RRID:AB_2632901
  Armenian Hamster monoclonal anti-CD103 (2E7) AI488                      BioLegend                  Cat\#121408; RRID:AB_535950
  Armenian Hamster monoclonal anti-CD103 (2E7) Biotin                     BioLegend                  Cat\#121403; RRID:AB_535946
  Rat monoclonal anti-CD138 (281-2) BV605                                 BioLegend                  Cat\#142531; RRID:AB_2715767
  Armenian Hamster monoclonal anti-CD152 (CTLA4) (UC10-4F10-11) PE/Cy7    TONBO                      Cat\#60-1522-U025; RRID:AB_2621861
  Mouse monoclonal anti-CD161 (NK1.1) (PK136) PE                          TONBO                      Cat\#50-5941-U 100; RRID:AB_2621804
  Rat monoclonal anti-CD185 (CXCR5) (L138D7) Biotin                       BioLegend                  Cat\#145510; RRID:AB_2562126
  Rat monoclonal anti-CD278 (ICOS) (7E.17G9) PE                           BioLegend                  Cat\#117405; RRID:AB_961244
  Rat monoclonal anti-CD278 (ICOS) (7E.17G9) PE/Cy7                       eBioscience                Cat\#25-9942-82; RRID:AB_2573564
  Rat monoclonal anti-CD279 (PD-1) (RMP1-30) APC                          eBioscience                Cat\#17-9981-80; RRID:AB_10853186
  Rat monoclonal anti-CD304 (Neuropilin-1) (3E 12) APC                    BioLegend                  Cat\#145205; RRID:AB_2562031
  Rat monoclonal anti-CD366 (Tim-3) (RMT3-23) PE/Cy7                      BioLegend                  Cat\#119715; RRID:AB_2571932
  Rat monoclonal anti-Lag3 (C9B7W) PE                                     BioLegend                  Cat\#125207; RRID:AB_2133344
  Rat monoclonal anti-GL7 (GL7) PE                                        BioLegend                  Cat\#144608; RRID:AB_2562926
  Syrian hamster monoclonal anti-KLRG1 (MAFA) (2F1/KLRG1) Biotin          BioLegend                  Cat\#138406; RRID:AB_10575641
  Armenian Hamster monoclonal anti-TCR β (H57-597) Al488                  BioLegend                  Cat\#109215; RRID:AB_493344
  Armenian Hamster monoclonal anti-TCR β (H57-597) APC/Cy7                BioLegend                  Cat\#109220; RRID:AB_893624
  Armenian Hamster monoclonal anti-TCR β (H57-597) PE-Cy7                 BioLegend                  Cat\#109222; RRID:AB_893625
  Armenian Hamster monoclonal anti-TCR γ/δ (GL3) PE                       BioLegend                  Cat\#118108; RRID:AB_313832
  Armenian Hamster monoclonal anti-TCR γ/δ (eBioGL3) Biotin               eBioscience                Cat\#13-5711-85; RRID:AB_466669
  Rat monoclonal anti-TER-119/Erythroid Cells (TER-119) Biotin            BioLegend                  Cat\#116204; RRID:AB_313705
  Mouse monoclonal anti-BCL-6 (K112-91) Al647                             BD PharMingen              Cat\#561525; RRID:AB_10898007
  Rabbit monoclonal anti-Bim (C34C5) Al488                                Cell Signaling             Cat\#94805S; RRID not available
  Rabbit monoclonal anti-Bim (C34C5) Al647                                Cell Signaling             Cat\#10408S; RRID not available
  Rat monoclonal anti-Blimp1 (5E7) PE                                     BD PharMingen              Cat\#564268; RRID:AB_2738718
  Rabbit monoclonal anti-active Caspase-3 (C92-605) PE                    BD Bioscience              Cat\#561011; RRID:AB_2033931
  Rat monoclonal anti-Foxp3 (FJK-16 s) APC                                eBioscience                Cat\#17-5773-82; RRID:AB_469457
  Rat monoclonal anti-Foxp3 (FJK-16 s) eF450                              eBioscience                Cat\#48-5773-82; RRID:AB_1518812
  Rat monoclonal anti-GFP/YFP (5F12.4) PerCP-eFluor 710                   eBioscience                Cat\#46-6498-80; RRID:AB_11042700
  Armenian Hamster monoclonal anti-Helios (22F6) PE                       BioLegend                  Cat\#137206; RRID:AB_315400
  Rat monoclonal anti-IFNγ (XMG1.2) FITC                                  BioLegend                  Cat\#505806; RRID:AB_315402
  Rat monoclonal anti-IgD (11-26c.2a) Pacific Blue                        BioLegend                  Cat\#405711; RRID:AB_10899576
  Rat monoclonal anti-IL-17A (TC11-18H10.1) APC                           BioLegend                  Cat\#506916; RRID:AB_961384
  Rat monoclonal anti-IRF4 (IRF4.3E4) Al488                               BioLegend                  Cat\#646406; RRID:AB_2563004
  Rat monoclonal anti-IRF4 (IRF4.3E4) PE                                  BioLegend                  Cat\#646403; RRID:AB_2266296
  Mouse monoclonal anti-KI-67 (B56) PE                                    BD PharMingen              Cat\#556027; RRID:AB_10611574
  Mouse monoclonal anti-KI-67 (B56) PerCP/Cy5.5                           BD PharMingen              Cat\#561284; RRID:AB_10949502
  Rabbit monoclonal anti-LEF1 (C12A5) Al488                               Cell Signaling             Cat\#8490S; RRID:AB_10949503
  Rabbit monoclonal anti-LEF1 (C12A5) PE                                  Cell Signaling             Cat\#14440S; RRID:AB_1257210
  Mouse monoclonal anti-Nur77 (12.14) PE                                  eBioscience                Cat\#12-5965-80; RRID:AB_2573310
  Mouse monoclonal anti-Stat5a + Stat5b (A-9) Al647                       Santa Cruz Biotechnology   Cat\#sc-74442 AF647; RRID not available
  Mouse monoclonal anti-Phospho-Stat5(pY694) (47) PE                      BD Phosflow                Cat\#612567; RRID:AB_2572664
  Rat monoclonal anti-RORgt (B2D) PerCP-eFluor710                         eBioscience                Cat\#46-6981-82; RRID:AB_1595466
  Rabbit monoclonal anti-TCF1 (C63D9) Al647                               Cell Signaling             Cat\#6709S; RRID not available
  Armenian Hamster monoclonal anti-CD3ε (145-2C11)                        BioLegend                  Cat\#100340; RRID:AB_11149115
  Rat monoclonal anti-CD16/CD32 (2.4G2)                                   TONBO                      Cat\#70-0161-U500; RRID:AB_2621487
  Syrian Hamster monoclonal anti-CD28 (37.51)                             BioLegend                  Cat\#102112; RRID:AB_312877
  SA PerCP/Cy5.5                                                          BioLegend                  Cat\#405214; RRID:AB_2716577
  SA Al488                                                                BioLegend                  Cat\#405235; RRID not available
  SA PECy7                                                                BioLegend                  Cat\#405206; RRID not available
  Bacterial and Virus Strains                                                                        
  pCL-Eco                                                                                            Addgene; Plasmid \#12371
  pMIGRI                                                                  [@R7]                      N/A
  pMIGRI-Tcf7-long                                                        [@R7]                      N/A
  pMIGRI-caSTAT5b                                                         [@R28]                     N/A
  Chemicals, Peptides, and Recombinant Proteins                                                      
  Recombinant Human IL-2                                                  PeproTech                  Cat\#AF-200-02
  Critical Commercial Assays                                                                         
  LIVE/DEAD fixable Aqua dead cell stain kit                              Thermo Fisher Scientific   Cat\#L34966
  eBioscience Foxp3 / Transcription Factor Staining Buffer Set            Thermo Fisher Scientific   Cat\#00-5523-00
  TruSeq® Stranded mRNA LT - Set A                                        Illumina                   Cat\#RS-122-2101
  truChIP Chromatin Shearing Kit with Formaldehyde                        Covaris                    Cat\#520154
  BD Cytofix/Cytoperm solution                                            BD                         Cat\#554722
  CellTrace Violet Cell Proliferation Kit, for flow cytometry             Thermo Fisher Scientific   Cat\# C34557
  Mouse Anti-dsDNA Ig's (Total A+G+M) ELISA Kit, 96 tests, Quantitative   Alpha Diagnostic           Cat\#5110
  Mouse Ig Isotyping ELISA Ready-Set-Go!® 10 × 96 tests                   eBioscience                Cat\#88-50630-88
  Deposited Data                                                                                     
  Raw and analyzed data                                                   This paper                 GEO: GSE117726
  Experimental Models: Cell Lines                                                                    
  293T cells                                                              [@R7]                      RRID:CVCL_0063
  Experimental Models: Organisms/Strains                                                             
  Mouse: C57BL/6: C57BL/6J                                                The Jackson Laboratory     RRID:IMSR_JAX:000664
  Mouse: Foxp3^YFP-Cre^: B6.129(Cg)-*Foxp3^tm4(YFP/icre)Ayr^*/J           The Jackson Laboratory     RRID:IMSR_JAX:016959
  Mouse: B6/CD45.1: B6.SJL-*Ptprc^a^ PepC^b^*/BoyJ                        The Jackson Laboratory     RRID:IMSR_JAX:002014
  Mouse: B6/*Tcrα*^−/−^: B6.129S2-*Tcra^tm1Mom^*/J                        The Jackson Laboratory     RRID:IMSR_JAX:002116
  Mouse: B6/*Rag1*^−/−^: B6.129S7-*Rag1^tm1Mom^*/J                        The Jackson Laboratory     RRID:IMSR_JAX:002216
  Mouse: *Foxp3^Thy1.1^*                                                  [@R38]                     N/A
  Mouse: *Tcf7^GFP^*                                                      [@R8]                      N/A
  Mouse: *Tcf7^fl/fl^*                                                    [@R78]                     N/A
  Mouse: *Lef1^f1/f1^*                                                    [@R58]                     N/A
  Oligonucleotides                                                                                   
  ChIP-PCR Primer: Bcl6 --0.5K_F GGGTCTGGGGCTAATTCTTC                     [@R75]                     N/A
  ChIP-PCR Primer: Bcl6 --0.5K_R TAGCTGGAAGGAGCTGTGGT                     [@R75]                     N/A
  ChIP-PCR Primer: Stat5b\_ F TCAGCTCCGTGTGGTTTCTAAC                      This paper                 N/A
  ChIP-PCR Primer: Stat5b\_ R TTCATCTCGAGCTGGGTGTTC                       This paper                 N/A
  Software and Algorithms                                                                            
  FlowJo                                                                  FlowJo, LLC                <https://www.flowjo.com/solutions/flowjo/downloads>
  GraphPad Prism 6                                                        GraphPad Software          <https://www.graphpad.com/scientific-software/prism/>
  STAR                                                                    [@R15]                     <https://code.google.com/archive/p/rna-star/>
  Cuffdiff                                                                [@R66]                     <https://software.broadinstitute.org/cancer/software/genepattern/modules/docs/Cuffdiff/7>
  Extraction of Differential Gene Expression (EDGE)                       [@R32]                     <https://github.com/StoreyLab/edge>
  Gene Set Enrichment Assay (GSEA)                                        [@R60]                     <http://software.broadinstitute.org/gsea/index.jsp>
  GenePattern software package                                            [@R49]                     <http://software.broadinstitute.org/cancer/software/genepattern/use-genepattern>
  BISMA                                                                   [@R51]                     <http://services.ibc.uni-stuttgart.de/BDPC/BISMA/> RRID:SCR_000688

###### Highlights

-   The expression of TCF1 and LEF1 distinguishes Treg cells into distinct subsets

-   Treg-specific ablation of TCF1 and LEF1 provokes systemic autoimmunity

-   TCF1 and LEF1 are essential for Treg's competitive fitness and survival

-   TCF1 and LEF1 are indispensable for the development of Tfr, a subset of aTregs
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